Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
Processa Pharmaceuticals has announced positive results from their Phase 1b trial of NGC-Cap in gastrointestinal cancer patients. The trial involved 12 patients, with 66.7% achieving progression-free survival (PFS) ranging from 5 to 11 months. At the highest dose, all patients showed PFS, with two partial responses and one stable disease. Compared to monotherapy capecitabine, 5-FU exposure was greater, and FBAL exposure was lower, with better or similar side effects. These promising results support further development, with a Phase 2 trial in breast cancer slated for the third quarter of 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
3
+0
Translate
Report
1395 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    844Followers
    62Following
    5611Visitors
    Follow